Edition:
United States

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

17.97USD
4:00pm EDT
Change (% chg)

$0.51 (+2.92%)
Prev Close
$17.46
Open
$17.52
Day's High
$18.10
Day's Low
$17.28
Volume
431,751
Avg. Vol
454,831
52-wk High
$20.85
52-wk Low
$1.36

Chart for

About

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin... (more)

Overall

Beta: 0.35
Market Cap(Mil.): $1,387.29
Shares Outstanding(Mil.): 79.46
Dividend: --
Yield (%): --

Financials

  ECYT.OQ Industry Sector
P/E (TTM): -- 103.50 32.14
EPS (TTM): -1.05 -- --
ROI: -36.76 1.52 12.66
ROE: -36.90 0.25 14.84

BRIEF-Endocyte Reports Q1 Loss Per Share $0.16

* Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S

May 09 2018

BRIEF-Endocyte Says Data Presented At AACR Show That EC17 Penetrates Solid Tumors Within Minutes And Is Retained Due To High Affinity For Folate Receptor

* ENDOCYTE INC - DATA PRESENTED AT AACR SHOW THAT EC17 PENETRATES SOLID TUMORS WITHIN MINUTES AND IS RETAINED DUE TO HIGH AFFINITY FOR FOLATE RECEPTOR Source text for Eikon: Further company coverage:

Apr 16 2018

Competitors

Earnings vs. Estimates